Canada’s Drug Agency Issues Recommendation to Reimburse Yorvipath® (palopegteriparatide injection) With Conditions for Eligible Adults With Chronic Hypoparathyroidism

Canada’s Drug Agency Issues Recommendation to Reimburse Yorvipath® (palopegteriparatide injection) With Conditions for Eligible Adults With Chronic Hypoparathyroidism →

Recommendation is an important step toward potential public reimbursement for eligible adults whose chronic hypoparathyroidism is not adequately controlled with conventional therapy MONTREAL, Sept. 03, 2026 (GLOBE NEWSWIRE) — Pendopharm, a…